Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc demonstrated robust revenue growth, with Cell Processing revenue reaching $23.0 million, representing a year-over-year increase of 28%, and total revenue for the second quarter of 2025 hitting $25.4 million, marked by a 29% year-over-year growth. The company has raised its 2025 revenue guidance to a range of $100-103 million, signaling a projected growth of 22-25% compared to the previous year, bolstered by sustained traction in both Cell Processing and evo and Thaw services. Management's expectations of improved adjusted EBITDA margins and reduced net losses further underscore the company's strong financial foundation and growth trajectory within the cell and gene therapy industry.

Bears say

BioLife Solutions Inc. faces several substantial risks, including lower-than-projected growth of its products and services, challenges in securing new customers, and fluctuations in sales due to emerging market dynamics and foreign exchange rates, which collectively contribute to a negative outlook. The company reported a net loss of $15.8 million, significantly higher than the estimated loss of $2.0 million, largely driven by in-process R&D expenses related to the PanTHERA transaction. Additionally, management's revision of FY2025 revenue guidance to $95.0-96.0 million, reflecting a decline of approximately $8 million in expected revenue, raises concerns about the company's growth trajectory, particularly given the reliance on the Cell Processing platform for the majority of revenue.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.